Prenatal pharmacotherapy rescues brain development in a Down's syndrome mouse model

Area of Science:

• Neuroscience
• Developmental Biology
• Genetics

Background:

• Down's syndrome (trisomy 21) is characterized by significant intellectual impairment due to impaired neurogenesis and abnormal brain development.
• Current treatments for cognitive deficits in Down's syndrome are limited, with most pharmacotherapies tested in adult models.
• Neurogenesis primarily occurs prenatally, suggesting that early intervention is crucial for correcting developmental abnormalities.

Purpose of the Study:

• To investigate the efficacy of prenatal fluoxetine therapy in rescuing neurodevelopmental deficits in the Ts65Dn mouse model of Down's syndrome.
• To determine if embryonic treatment can restore neurogenesis, brain structure, and cognitive function in Down's syndrome models.

Main Methods:

• Pregnant Ts65Dn mice received fluoxetine from embryonic Day 10 until delivery.
• Postnatal pups were assessed for neurogenesis, cellularity, dendritic development, and synapse formation at different time points.
• Behavioral performance was evaluated in treated and untreated mice.

Main Results:

• Prenatal fluoxetine fully restored precursor cell proliferation and cellularity throughout the brain in Ts65Dn mice.
• The treatment also rescued dendritic development, synapse formation, and brain volume.
• Treated mice showed significant recovery of behavioral performance compared to untreated controls.

Conclusions:

• Prenatal pharmacotherapy with fluoxetine can effectively rescue abnormal brain development and associated behavioral deficits in a mouse model of Down's syndrome.
• This study provides evidence that targeting neurogenesis during embryonic development may reverse the cognitive impairments of Down's syndrome.
• Fluoxetine, a human-usable drug, may offer a novel therapeutic strategy for intellectual disability in Down's syndrome if findings translate to human fetuses.